CN105246481A - 用于p53再活化的低聚氧代哌嗪 - Google Patents

用于p53再活化的低聚氧代哌嗪 Download PDF

Info

Publication number
CN105246481A
CN105246481A CN201480010794.8A CN201480010794A CN105246481A CN 105246481 A CN105246481 A CN 105246481A CN 201480010794 A CN201480010794 A CN 201480010794A CN 105246481 A CN105246481 A CN 105246481A
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480010794.8A
Other languages
English (en)
Chinese (zh)
Inventor
P·S·阿罗拉
Q·潘
A·马普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
University of Michigan Ann Arbor
Ohio State University Research Foundation
Original Assignee
New York University NYU
University of Michigan Ann Arbor
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU, University of Michigan Ann Arbor, Ohio State University Research Foundation filed Critical New York University NYU
Publication of CN105246481A publication Critical patent/CN105246481A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480010794.8A 2013-01-19 2014-01-21 用于p53再活化的低聚氧代哌嗪 Pending CN105246481A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754575P 2013-01-19 2013-01-19
US61/754,575 2013-01-19
PCT/US2014/012337 WO2014113794A2 (en) 2013-01-19 2014-01-21 Oligooxopiperazines for p53 reactivation

Publications (1)

Publication Number Publication Date
CN105246481A true CN105246481A (zh) 2016-01-13

Family

ID=51207874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480010794.8A Pending CN105246481A (zh) 2013-01-19 2014-01-21 用于p53再活化的低聚氧代哌嗪

Country Status (7)

Country Link
US (1) US9695153B2 (https=)
EP (1) EP2945631A4 (https=)
JP (1) JP2016510327A (https=)
CN (1) CN105246481A (https=)
AU (1) AU2014207311A1 (https=)
CA (1) CA2898329A1 (https=)
WO (1) WO2014113794A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3145921A4 (en) 2014-05-21 2017-11-08 New York University Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3724178B1 (en) 2017-12-15 2024-05-01 Inthera Bioscience AG 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054184A1 (en) * 2006-11-03 2008-05-08 Seoul National University Industry Foundation Composition for treatment of cervix cancer
US20120040992A1 (en) * 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
CN104334541A (zh) * 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3542230A1 (de) 1985-11-29 1987-06-04 Bayer Ag Verfahren zur herstellung von oligomeren und telechelen mit carboxy-piperazin-einheiten und neue oligomere und telechele des poly(carboxypiperazins)
GB9022790D0 (en) 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
AU4432496A (en) 1994-12-23 1996-07-19 Dr. Karl Thomae Gmbh Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
FR2803594B1 (fr) 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US6841675B1 (en) 2002-06-13 2005-01-11 The Regents Of The University Of California Piperazine-based nucleic acid analogs
WO2009097486A1 (en) 2008-01-31 2009-08-06 The Scripps Research Institute OXAZOLE-PYRROLE-PIPERAZINE α-HELIX MIMETIC
US9399666B2 (en) 2008-09-18 2016-07-26 New York University Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054184A1 (en) * 2006-11-03 2008-05-08 Seoul National University Industry Foundation Composition for treatment of cervix cancer
US20120040992A1 (en) * 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
CN104334541A (zh) * 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制

Also Published As

Publication number Publication date
WO2014113794A3 (en) 2014-09-12
WO2014113794A2 (en) 2014-07-24
US9695153B2 (en) 2017-07-04
EP2945631A2 (en) 2015-11-25
CA2898329A1 (en) 2014-07-24
EP2945631A4 (en) 2016-06-29
US20140205655A1 (en) 2014-07-24
AU2014207311A1 (en) 2015-08-20
JP2016510327A (ja) 2016-04-07

Similar Documents

Publication Publication Date Title
US9605026B2 (en) Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
KR102848852B1 (ko) 폴리펩티드, 이의 제조방법 및 용도
ES2808726T3 (es) Inmunotoxinas de unión a CD20 para inducir la internalización celular y procedimientos que usan las mismas
US11945875B2 (en) Motile sperm domain containing protein 2 and cancer
JP7307744B2 (ja) がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体
TW202136252A (zh) 化合物及其用途
JP2020536096A (ja) 腫瘍成長を阻害するための材料および方法
AU2014316030C1 (en) Antitumor agent and antitumor effect enhancer
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
US9695153B2 (en) Oligooxopiperazines for p53 reactivation
WO2015172563A1 (zh) 一种靶向eps8与egfr结合的短肽及其应用
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
WO2021178663A1 (en) Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors
US20110152200A1 (en) Methods and compositions for inhibition of bcl6 repression
US12281180B2 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
TW202241444A (zh) 治療或預防波形蛋白介導的疾病的化合物
JP2017500849A (ja) 細胞透過組成物およびそれを用いる方法
JP7244511B2 (ja) Ｌｙ６Ｋを阻害する化合物およびそれらを使用する方法
CA3140026A1 (en) Polypeptides for treatment of cancer
JP6760657B2 (ja) タイトジャンクションの緩和剤、該緩和剤を含む薬剤吸収補助剤、及び該緩和剤を含む医薬組成物
CN119950745B (zh) 一种药物组合物及其在制备抗肿瘤药物中的应用
CN114634551B (zh) 多肽及其在制备拮抗野生型p53与MDM2结合的抗癌药物中的应用
TW201934543A (zh) 以鋅結合劑為基礎的ｅｂｎａ１專一性化合物
RU2825271C2 (ru) Макроциклические соединения в качестве агонистов sting и способы с их использованием и пути их применения
KR20260040609A (ko) 티로신-단백질 키나제 막 수용체 1(ror1) 항체-약물 접합체 및 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160113

WD01 Invention patent application deemed withdrawn after publication